Steve Horvath at ARDD2026: Surrogate endpoints for veterinary geroprotector trials

Steve Horvath at ARDD2026: Surrogate endpoints for veterinary geroprotector trials

by Steve Horvath · View the channel on PSI

Life & Natural Systems Medicine & Health MZAVeterinary medicine: generalMZABVeterinary medicine: research
🎙 Steve Horvath 👥 9K 📅 October 20, 2026 ⏱ 23 min 👁 20 📄 original study 🧭 2026-10-20
Available in: English (current) Français

Keywords

surrogate endpointsveterinary trialsdog longevityepigenetic clockscaloric restriction

Summary

Steve Horvath presents evidence that DNA methylation clocks are the most promising surrogate endpoints for veterinary geroprotector trials, particularly in dogs. He reviews a landmark 14-year study on caloric restriction in 48 Labrador dogs, which extended lifespan, and notes that such long trials are impractical for biotech companies. He highlights that the FDA has recognized dog lifespan as a regulatory indicator on the conditional approval track, opening a path for faster drug approvals. The talk explains why methylation clocks are suitable: they are accurate, stable, predictive of mortality, responsive to interventions, and largely conserved across mammalian species. He discusses the development of the mammalian methylation array (MamMethyl array) targeting 36,000 conserved CpGs, which enabled the creation of clocks for dogs, cats, horses, and other species. The analysis shows that clocks trained on both humans and dogs can accurately measure relative age (age divided by maximum lifespan). He also addresses the effect of caloric restriction, which was detected by multiple clocks seven years before the survival curves diverged, supporting the utility of clocks as early indicators. Breed differences were surprisingly small, but a deeper analysis revealed some methylomic modules correlating with breed. He mentions an androgen exposure clock in sheep, demonstrating the potential for mechanistic clocks. Finally, he outlines gaps to bridge: test-retest variability, analytical validation, and evidence that clocks consistently reflect functional outcomes across many interventional studies.

227 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of the information is high, as it offers a clear, evidence-based case for using methylation clocks as surrogate endpoints in veterinary trials. Horvath logically moves from the problem (long, costly lifespan trials) to a solution (validated biomarkers), and supports his argument with specific examples: the dog caloric restriction study, the FDA’s conditional approval pathway, and the responsiveness of clocks to interventions. He strengthens his argument by acknowledging limitations—such as the need for multiple clocks to corroborate effects and the unresolved sex differences—and by proposing concrete next steps (e.g., building organ-age clocks for pets). The reasoning is solid, and he avoids overstating conclusions, explicitly stating that no clock is yet qualified as a surrogate endpoint.

Scientific Rigor, Source Quality, Title Accuracy

The talk demonstrates rigorous scientific practice: Horvath references numerous peer-reviewed studies, including his own published work, the Gladyshev lab’s mouse studies, and the Nestlé and Purina dog trial. He emphasizes public data availability (e.g., the Mammalian Methylation Consortium’s >15,000 samples across 348 species) and correctly notes that the evidence base is growing but incomplete. The title precisely matches the subject matter, accurately reflecting the talk’s focus on surrogate endpoints and veterinary geroprotector trials. No comments were provided for analysis, so this section omits any assessment of public reception.

219 words

Title / Content Match

The title accurately reflects the talk's focus on surrogate endpoints for veterinary geroprotector trials, specifically showcasing methylation clocks as prime candidates.

Quality & Reliability

9/10

Presentation by a leading expert in epigenetic clocks, referencing multiple peer-reviewed studies including the 14-year Labrador dog caloric restriction study and the Mammalian Methylation Consortium. The speaker clearly distinguishes established findings from speculative applications and acknowledges limitations such as the need for larger sample sizes and validation of surrogate endpoints.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

Contribution & Novelties

Horvath’s contribution is a compelling argument that dogs—and other pets—are a more practical setting than humans for qualifying surrogate endpoints, because they have shorter lifespans and allow better experimental control. He offers proof-of-concept that methylation clocks detected caloric restriction effects years before survival curves diverged, and he introduces the idea of creating organ-age clocks for pets. The talk also highlights the power of the mammalian methylation array for cross-species comparative biology, which could accelerate the translation of veterinary findings to human aging.

Pour aller plus loin :

  • Epigenetic clock — A comprehensive overview of the concept, including its history and applications.
  • Surrogate endpoint — Definition and examples, relevant to the talk’s central theme.
  • Caloric restriction — The intervention studied in the dog trial, with evidence from various model organisms.

129 words

Radar Profile

The radar profile shows consistently high scores across all dimensions, indicating a well-rounded and reliable presentation. The strong quantitative and qualitative scores reflect dense, technical content delivered with authority, while the equally high reliability score underscores the credibility of the speaker and the supporting references.

Reliability 9/10